Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study.
Saved in:
| Title: | Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study. |
|---|---|
| Authors: | Yi, Zongbi1 (AUTHOR) yizongbi@163.com, Ma, Fei1 (AUTHOR) drmafei@126.com, Liu, Binliang1 (AUTHOR) liubinliang_onco@163.com, Guan, Xiuwen1 (AUTHOR) guanxiuwen@foxmail.com, Li, Lixi1 (AUTHOR) 1054983057@qq.com, Li, Chunxiao2 (AUTHOR) campuscx@163.com, Qian, Haili2 (AUTHOR) qianhaili001@163.com, Xu, Binghe1 (AUTHOR) bhxu@hotmail.com |
| Source: | BMC Cancer. 5/14/2019, Vol. 19 Issue 1, p1-9. 9p. 1 Chart, 6 Graphs. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: asn DbLabel: Academic Search Ultimate An: 136440963 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Yi%2C+Zongbi%22">Yi, Zongbi</searchLink><relatesTo>1</relatesTo> (AUTHOR)<i> yizongbi@163.com</i><br /><searchLink fieldCode="AR" term="%22Ma%2C+Fei%22">Ma, Fei</searchLink><relatesTo>1</relatesTo> (AUTHOR)<i> drmafei@126.com</i><br /><searchLink fieldCode="AR" term="%22Liu%2C+Binliang%22">Liu, Binliang</searchLink><relatesTo>1</relatesTo> (AUTHOR)<i> liubinliang_onco@163.com</i><br /><searchLink fieldCode="AR" term="%22Guan%2C+Xiuwen%22">Guan, Xiuwen</searchLink><relatesTo>1</relatesTo> (AUTHOR)<i> guanxiuwen@foxmail.com</i><br /><searchLink fieldCode="AR" term="%22Li%2C+Lixi%22">Li, Lixi</searchLink><relatesTo>1</relatesTo> (AUTHOR)<i> 1054983057@qq.com</i><br /><searchLink fieldCode="AR" term="%22Li%2C+Chunxiao%22">Li, Chunxiao</searchLink><relatesTo>2</relatesTo> (AUTHOR)<i> campuscx@163.com</i><br /><searchLink fieldCode="AR" term="%22Qian%2C+Haili%22">Qian, Haili</searchLink><relatesTo>2</relatesTo> (AUTHOR)<i> qianhaili001@163.com</i><br /><searchLink fieldCode="AR" term="%22Xu%2C+Binghe%22">Xu, Binghe</searchLink><relatesTo>1</relatesTo> (AUTHOR)<i> bhxu@hotmail.com</i> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22BMC+Cancer%22">BMC Cancer</searchLink>. 5/14/2019, Vol. 19 Issue 1, p1-9. 9p. 1 Chart, 6 Graphs. |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=136440963 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1186/s12885-019-5668-3 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 9 StartPage: 1 Titles: – TitleFull: Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Yi, Zongbi – PersonEntity: Name: NameFull: Ma, Fei – PersonEntity: Name: NameFull: Liu, Binliang – PersonEntity: Name: NameFull: Guan, Xiuwen – PersonEntity: Name: NameFull: Li, Lixi – PersonEntity: Name: NameFull: Li, Chunxiao – PersonEntity: Name: NameFull: Qian, Haili – PersonEntity: Name: NameFull: Xu, Binghe IsPartOfRelationships: – BibEntity: Dates: – D: 14 M: 05 Text: 5/14/2019 Type: published Y: 2019 Identifiers: – Type: issn-print Value: 14712407 Numbering: – Type: volume Value: 19 – Type: issue Value: 1 Titles: – TitleFull: BMC Cancer Type: main |
| ResultId | 1 |